Description: View BIKTARVY® (bictegravir, emtricitabine, tenofovir alafenamide) clinical trials for treatment-naïve adults. Read full Prescribing Info, including BOXED WARNING.
BIKTARVY ® is indicated as a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing ≥14 kg who have no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies per mL) on a stable ARV regimen with no history of treatment failure and no known resistance to any component of BIKTARVY.
Supported by 240 weeks of robust clinical trial data, including 96-week open-label extension data 1-3
BIKTARVY is being studied in additional clinical trials